Overview

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Status:
Recruiting

Trial end date:
2023-11-16

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well antiandrogen therapy, abiraterone acetate, and prednisone with or without neutron radiation therapy work in treating patients with prostate cancer. Hormone therapy such as antiandrogen therapy may fight prostate cancer by blocking the production and interfering with the action of hormones. Abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Neutron radiation therapy uses high energy neutrons to kill tumor cells and shrink tumors. It is not yet known whether antiandrogen therapy, abiraterone acetate, and prednisone with or without neutron radiation therapy may work better in treating patients with prostate cancer.

Phase:

Phase 2

Details

Lead Sponsor:

University of Washington

Collaborator:

National Cancer Institute (NCI)

Treatments:

Abiraterone Acetate
Androgen Antagonists
Androgens
Ascorbic Acid
Cortisone
Estrogens, Conjugated (USP)
Hormones
Methyltestosterone
Prednisone